Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154294 | 0.85 | KDM4E (0.34) | PTGS2DHODHKDM4EALDH1A1HPGD | |
| SCHEMBL2608091 | 0.82 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL548087 | 0.77 | CD274 (0.46) | PTGS2TUBB1PTGS1 | |
| SCHEMBL12865409 | 0.74 | MGLL (0.34) | PTGS2TUBB1PTGS1TDP2 | |
| SCHEMBL548987 | 0.72 | TUBB1 (0.41) | PTGS2TUBB1PTGS1TDP2 | |
| SCHEMBL2626383 | 0.72 | TUBB1 (0.41) | PTGS2TUBB1PTGS1TDP2 | |
| SCHEMBL23758390 | 0.72 | PTGS2 (0.41) | PTGS2PTGS1TDP2 | |
| SCHEMBL27006307 | 0.69 | ESR1 (0.58) | TUBB1DHODH | |
| SCHEMBL31741626 | 0.69 | ADRA1A (0.49) | PTGS2TUBB1PTGS1KDM4EALDH1A1 | |
| SCHEMBL23758388 | 0.68 | KDM4E (0.54) | PTGS2TDP2KDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101310-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY, AND METHOD FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF BY USING THE SAME | NAGASE & CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-8110680-B2 | Optically active quaternary ammonium salt having axial asymmetry, and method for producing alpha-amino acid and derivative thereof by using the same | NAGASE & CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100029935-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY, AND METHOD FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF BY USING THE SAME | NAGASE & CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101310-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY, AND METHOD FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF BY USING THE SAME | AADAT, BCAT1, BCAT2 | PTGS2 4706/4885TUBB1 798/4885PTGS1 4703/4885 |
| US-20100029935-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY, AND METHOD FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF BY USING THE SAME | AADAT, BCAT1, BCAT2 | PTGS2 4706/4885TUBB1 798/4885PTGS1 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.